{"id":"psa-dosage","safety":{"commonSideEffects":[{"rate":null,"effect":"Pain or discomfort during the biopsy procedure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PSA is a protein produced by the prostate gland, and elevated levels can indicate prostate cancer or other prostate conditions. The PSA dosage test measures the amount of PSA in the blood, which can help doctors diagnose and monitor prostate cancer, as well as monitor the effectiveness of treatment.","oneSentence":"PSA dosage is used to measure the level of prostate-specific antigen in the blood, which can help diagnose and monitor prostate cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:43.335Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer screening and monitoring"}]},"trialDetails":[{"nctId":"NCT04530552","phase":"PHASE2","title":"Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-23","conditions":"Localized Prostate Carcinoma, Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":34},{"nctId":"NCT04009499","phase":"PHASE3","title":"A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2019-08-13","conditions":"Psoriatic Arthritis","enrollment":1131},{"nctId":"NCT07493239","phase":"NA","title":"A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health","status":"RECRUITING","sponsor":"Lesaffre International","startDate":"2026-03","conditions":"Joint Health","enrollment":240},{"nctId":"NCT05678322","phase":"PHASE3","title":"Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-01-31","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT07489729","phase":"NA","title":"Hypo Fractionated Versus Conventional IMRT in Unfavorable Intermediate- and High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-06-30","conditions":"Hypofractionated Dose, Prostate Cancer Patients","enrollment":60},{"nctId":"NCT07286058","phase":"PHASE3","title":"Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-03-11","conditions":"Psoriatic Arthritis","enrollment":1182},{"nctId":"NCT07145437","phase":"NA","title":"Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer (PROSTERA)","status":"NOT_YET_RECRUITING","sponsor":"Clinique Sainte Clotilde","startDate":"2026-04-01","conditions":"Prostate Cancer","enrollment":220},{"nctId":"NCT04206319","phase":"PHASE2","title":"Radium-223 in Biochemically Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Biochemical Recurrent Prostate Cancer","enrollment":19},{"nctId":"NCT07259213","phase":"PHASE1, PHASE2","title":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","status":"RECRUITING","sponsor":"Radiopharm Theranostics, Ltd","startDate":"2026-03-05","conditions":"Castration-resistant Prostate Cancer","enrollment":73},{"nctId":"NCT05884398","phase":"PHASE3","title":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-31","conditions":"Metastatic Castrate-sensitive Prostate Cancer","enrollment":420},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT06671483","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-03","conditions":"Psoriatic Arthritis","enrollment":1088},{"nctId":"NCT06671496","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-10","conditions":"Psoriatic Arthritis","enrollment":600},{"nctId":"NCT06869551","phase":"PHASE3","title":"A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-03-13","conditions":"Juvenile Psoriatic Arthritis","enrollment":60},{"nctId":"NCT07190300","phase":"PHASE1, PHASE2","title":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-01-13","conditions":"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":155},{"nctId":"NCT06506916","phase":"PHASE3","title":"A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-07-29","conditions":"Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis","enrollment":90},{"nctId":"NCT01171898","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2010-07-26","conditions":"Prostate Cancer","enrollment":127},{"nctId":"NCT03568188","phase":"PHASE2","title":"Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-09-28","conditions":"Prostate Cancer","enrollment":174},{"nctId":"NCT03388619","phase":"PHASE1","title":"Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-17","conditions":"Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer","enrollment":30},{"nctId":"NCT05720130","phase":"PHASE1, PHASE2","title":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","status":"RECRUITING","sponsor":"AdvanCell Pty Limited","startDate":"2023-03-15","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer","enrollment":100},{"nctId":"NCT06450106","phase":"PHASE1","title":"Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy","status":"RECRUITING","sponsor":"SURGE Therapeutics","startDate":"2025-05-08","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT06631521","phase":"PHASE1","title":"Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer","status":"RECRUITING","sponsor":"AdventHealth","startDate":"2024-10-22","conditions":"Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery","enrollment":30},{"nctId":"NCT04997018","phase":"PHASE2","title":"A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-08-04","conditions":"Prostate Cancer","enrollment":91},{"nctId":"NCT07221825","phase":"NA","title":"Low-Count Quantitative SPECT for Men Treated With Radium-223","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-01","conditions":"Prostate Cancer, Cancer of the Prostate","enrollment":38},{"nctId":"NCT03796767","phase":"PHASE2","title":"Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2019-09-09","conditions":"Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes","enrollment":20},{"nctId":"NCT03896581","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-03-28","conditions":"Psoriatic Arthritis","enrollment":400},{"nctId":"NCT03895203","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-04-03","conditions":"Psoriatic Arthritis","enrollment":852},{"nctId":"NCT07333066","phase":"PHASE3","title":"Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.","status":"NOT_YET_RECRUITING","sponsor":"Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD","startDate":"2026-03-31","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":320},{"nctId":"NCT06600698","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2025-05-07","conditions":"Prostate Cancer","enrollment":45},{"nctId":"NCT07313241","phase":"PHASE2","title":"Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-11-14","conditions":"Prostate Cancer","enrollment":68},{"nctId":"NCT05766371","phase":"PHASE2","title":"Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-12-15","conditions":"Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","enrollment":48},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":"Prostate Cancer","enrollment":504},{"nctId":"NCT03833921","phase":"PHASE2","title":"Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer","status":"RECRUITING","sponsor":"Martha Mims","startDate":"2019-05-23","conditions":"Prostate Cancer Metastatic, Prostate Cancer","enrollment":130},{"nctId":"NCT05189457","phase":"PHASE2","title":"First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-01-25","conditions":"Prostate Cancer, Stage IV Prostate Cancer","enrollment":32},{"nctId":"NCT06594926","phase":"PHASE2","title":"Working Out M0 Bipolar Androgen Therapy","status":"RECRUITING","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2024-08-14","conditions":"Prostate Cancer","enrollment":69},{"nctId":"NCT05914116","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2023-08-17","conditions":"Advanced Solid Tumors","enrollment":862},{"nctId":"NCT04908202","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-13","conditions":"Psoriatic Arthritis","enrollment":670},{"nctId":"NCT04838613","phase":"PHASE3","title":"Study of Diagnostic Performance of [18F]CTT1057 in BCR","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-30","conditions":"Prostatic Neoplasms, Prostate Cancer, Recurrence","enrollment":190},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT07200830","phase":"PHASE3","title":"Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial","status":"NOT_YET_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-10-08","conditions":"Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":1524},{"nctId":"NCT06604442","phase":"PHASE4","title":"Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2024-12-04","conditions":"Prostate Cancer","enrollment":55},{"nctId":"NCT05107674","phase":"PHASE1","title":"A Study of NX-1607 in Adults With Advanced Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2021-09-29","conditions":"Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer","enrollment":345},{"nctId":"NCT07145281","phase":"NA","title":"Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2022-11-10","conditions":"Gender Dysphoria, Adult, Blood Coagulation, Coagulation Factors","enrollment":30},{"nctId":"NCT06395883","phase":"","title":"Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2025-01-01","conditions":"Osteoporosis, Osteoporosis, Steroid Induced, Inflammatory Rheumatism","enrollment":160},{"nctId":"NCT05855967","phase":"PHASE4","title":"A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-06-27","conditions":"Plaque Psoriasis, Psoriatic Arthritis","enrollment":250},{"nctId":"NCT05524519","phase":"NA","title":"Intradermal Acupuncture Based on Changes in Biological Specificity of Acupoints for Major Depressive Disorder","status":"COMPLETED","sponsor":"The Third Affiliated hospital of Zhejiang Chinese Medical University","startDate":"2022-11-01","conditions":"Major Depressive Disorder","enrollment":160},{"nctId":"NCT04319783","phase":"PHASE2","title":"Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2021-06-02","conditions":"Advanced Prostate Carcinoma, Cancer of Prostate, PSA","enrollment":65},{"nctId":"NCT04181203","phase":"PHASE3","title":"Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-01-09","conditions":"Prostate Cancer","enrollment":490},{"nctId":"NCT02923180","phase":"PHASE2","title":"Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-14","conditions":"Prostate Cancer","enrollment":33},{"nctId":"NCT06998043","phase":"PHASE2","title":"Study With Phage for CF Subjects With Pseudomonas Lung Infection","status":"RECRUITING","sponsor":"BiomX Ltd","startDate":"2025-07-02","conditions":"Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)","enrollment":63},{"nctId":"NCT05010577","phase":"PHASE1, PHASE2","title":"Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection","status":"COMPLETED","sponsor":"BiomX, Inc.","startDate":"2022-06-21","conditions":"Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis","enrollment":43},{"nctId":"NCT04363164","phase":"PHASE2","title":"Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-08-19","conditions":"Castration Resistant Metastatic Prostate Cancer","enrollment":150},{"nctId":"NCT06520345","phase":"PHASE3","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-07-26","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":430},{"nctId":"NCT04249154","phase":"PHASE2","title":"Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2019-09-03","conditions":"Prostate Cancer","enrollment":77},{"nctId":"NCT03531099","phase":"PHASE3","title":"Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2018-10-02","conditions":"Prostate Cancer","enrollment":108},{"nctId":"NCT06982469","phase":"","title":"High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy","status":"RECRUITING","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2020-05-05","conditions":"Prostate Cancer, Prostatectomy, Local Recurrence of Malignant Tumor of Prostate","enrollment":20},{"nctId":"NCT04908189","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-15","conditions":"Psoriatic Arthritis","enrollment":729},{"nctId":"NCT05623345","phase":"PHASE2, PHASE3","title":"Psoriatic Arthritis Study of Izokibep","status":"TERMINATED","sponsor":"ACELYRIN Inc.","startDate":"2022-11-21","conditions":"Psoriatic Arthritis","enrollment":351},{"nctId":"NCT04067570","phase":"NA","title":"Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2019-11-07","conditions":"SBRT, Radical Prostatectomy","enrollment":30},{"nctId":"NCT04812431","phase":"PHASE1, PHASE2","title":"Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI","status":"RECRUITING","sponsor":"S.Biomedics Co., Ltd.","startDate":"2021-09-23","conditions":"Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion, Spinal Cord Injury at C5-C7 Level With Complete Lesion","enrollment":5},{"nctId":"NCT05582876","phase":"NA","title":"Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2023-01-10","conditions":"Prostate Cancer","enrollment":366},{"nctId":"NCT06765954","phase":"PHASE2","title":"Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-06-01","conditions":"High-risk Prostate Cancer","enrollment":20},{"nctId":"NCT01162135","phase":"PHASE2","title":"Digoxin for Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-09","conditions":"Prostate Cancer","enrollment":16},{"nctId":"NCT04262154","phase":"PHASE2","title":"Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-03","conditions":"Metastatic Prostate Cancer","enrollment":28},{"nctId":"NCT03087903","phase":"NA","title":"A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-01-18","conditions":"Prostate Cancer","enrollment":41},{"nctId":"NCT05523856","phase":"","title":"New Treatment Modalities for Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundacion IMIM","startDate":"2014-04","conditions":"Prostate Cancer","enrollment":480},{"nctId":"NCT04428203","phase":"PHASE1","title":"Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"Zin W Myint","startDate":"2020-08-03","conditions":"Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma","enrollment":21},{"nctId":"NCT01492751","phase":"","title":"Effectiveness of Localized Prostate Cancer Treatments","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundacion IMIM","startDate":"2003-04","conditions":"Prostate Cancer","enrollment":500},{"nctId":"NCT03436745","phase":"PHASE1","title":"The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-22","conditions":"Prostatic Neoplasms","enrollment":12},{"nctId":"NCT02319759","phase":"PHASE2","title":"Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-03-27","conditions":"Psoriatic Arthritis","enrollment":149},{"nctId":"NCT00223145","phase":"PHASE3","title":"Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abdenour Nabid","startDate":"2000-12","conditions":"Prostate Cancer","enrollment":600},{"nctId":"NCT05847166","phase":"NA","title":"A Phase 2/3,PSMA-T4, Prostate Cancer","status":"RECRUITING","sponsor":"NCBJ Polatom: Narodowe Centrum Badań Jądrowych Polatom","startDate":"2023-05-10","conditions":"Prostate Cancer","enrollment":80},{"nctId":"NCT06588907","phase":"NA","title":"Pain Palliation in Forearm Fractures in the Emergency Department","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2024-06-01","conditions":"Forearm Fracture, Radius Fractures, Ulnar Fracture","enrollment":85},{"nctId":"NCT05715125","phase":"PHASE2","title":"VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)","status":"TERMINATED","sponsor":"Ventyx Biosciences, Inc","startDate":"2023-01-31","conditions":"Psoriatic Arthritis","enrollment":205},{"nctId":"NCT01994239","phase":"PHASE2","title":"Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-12","conditions":"Adenocarcinoma of Prostate","enrollment":120},{"nctId":"NCT05010707","phase":"PHASE2","title":"Transgender Estradiol Affirming Therapy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-08-02","conditions":"Transgenderism","enrollment":39},{"nctId":"NCT01284920","phase":"PHASE1, PHASE2","title":"A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-11-02","conditions":"Prostate Cancer, Prostate Neoplasms, Castration Resistant Prostate Cancer (CRPC)","enrollment":47},{"nctId":"NCT04298112","phase":"","title":"PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2020-05-01","conditions":"Prostatic Neoplasms","enrollment":300},{"nctId":"NCT06669273","phase":"NA","title":"Oncological Prognosis of Prostate Lesions by Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2024-10","conditions":"Suspected Prostate Cancer (increased PSA Level)","enrollment":70},{"nctId":"NCT03747939","phase":"PHASE4","title":"Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-12-31","conditions":"Arthritis, Psoriatic","enrollment":310},{"nctId":"NCT04291664","phase":"PHASE1","title":"PK and Dose Escalation and Expansion Study of DST-2970","status":"TERMINATED","sponsor":"DisperSol Technologies, LLC","startDate":"2020-01-31","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT04711902","phase":"PHASE3","title":"Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-24","conditions":"Psoriatic Arthritis","enrollment":41},{"nctId":"NCT03894969","phase":"PHASE2","title":"Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-23","conditions":"Respiratory Disorders","enrollment":541},{"nctId":"NCT06531525","phase":"PHASE2","title":"Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-08-01","conditions":"Pregnancy Related, Protein S Deficiency","enrollment":48},{"nctId":"NCT06209853","phase":"","title":"Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient","status":"RECRUITING","sponsor":"Assiut University","startDate":"2024-01-20","conditions":"Prostatic Neoplasms","enrollment":59},{"nctId":"NCT04957290","phase":"PHASE1, PHASE2","title":"A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors","status":"TERMINATED","sponsor":"Noxopharm Limited","startDate":"2021-10-25","conditions":"Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors","enrollment":21},{"nctId":"NCT02933255","phase":"PHASE1, PHASE2","title":"PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-18","conditions":"Prostate Cancer","enrollment":24},{"nctId":"NCT03791060","phase":"PHASE2","title":"Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2019-04-03","conditions":"Necrobiosis Lipoidica Diabeticorum","enrollment":4},{"nctId":"NCT03572387","phase":"PHASE2","title":"A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-08-20","conditions":"Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer","enrollment":14},{"nctId":"NCT06371846","phase":"","title":"Comparative Study of the Surface Electrocardiogram Signals During the Implantation of Conduction System Pacing Devices","status":"RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2023-03-14","conditions":"Conduction Disorder, Pacemaker DDD","enrollment":78},{"nctId":"NCT06370598","phase":"PHASE1, PHASE2","title":"Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"Technophage, SA","startDate":"2024-09","conditions":"Pneumonia, Ventilator-Associated","enrollment":15},{"nctId":"NCT04871841","phase":"","title":"Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan","status":"COMPLETED","sponsor":"Karaganda Medical University","startDate":"2021-04-05","conditions":"Covid19, Vaccine Adverse Reaction","enrollment":82},{"nctId":"NCT03311555","phase":"PHASE2","title":"A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2018-03-28","conditions":"Prostate Cancer","enrollment":39},{"nctId":"NCT01802242","phase":"NA","title":"Tumor TARGET Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2012-10","conditions":"Prostate Cancer","enrollment":85},{"nctId":"NCT02280356","phase":"PHASE2","title":"Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-10-28","conditions":"Prostate Cancer","enrollment":45},{"nctId":"NCT03347110","phase":"PHASE2","title":"A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-11-22","conditions":"Psoriatic Arthritis","enrollment":184},{"nctId":"NCT04109976","phase":"PHASE3","title":"A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-08-13","conditions":"Psoriatic Arthritis","enrollment":214},{"nctId":"NCT01420861","phase":"PHASE2","title":"GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer","status":"TERMINATED","sponsor":"GTx","startDate":"2011-09","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT01867333","phase":"PHASE2","title":"Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-12","conditions":"Prostate Cancer","enrollment":57},{"nctId":"NCT04645420","phase":"NA","title":"Molecular Effects of Apremilast in the Synovium of Psoriatic Arthritis Patients","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2020-11-12","conditions":"Psoriatic Arthritis","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PSA dosage","genericName":"PSA dosage","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Biologic","firstApprovalDate":"","aiSummary":"PSA dosage is used to measure the level of prostate-specific antigen in the blood, which can help diagnose and monitor prostate cancer. Used for Prostate cancer screening and monitoring.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}